Table 4.
Prognostic Factors Associated with Overall Survival and Time to Progression
| Factor No. of Patients | Overall Survival | Time To Progression | ||||
|---|---|---|---|---|---|---|
| (n=152) | Univariate Analysis Multivariate Analysis Univariate Analysis Multivariate Analysis | |||||
| P Value | HR (95% CI) | P Value | P Value HR (95% CI) P Value | |||
| Age (Year) | 0.684 | 0.100 | ||||
| <65 | 99 | |||||
| ≥65 | 53 | |||||
| Gender | 0.103 | 0.900 | ||||
| Male | 136 | |||||
| Female | 16 | |||||
| ECOG (Score) | <0.001 | 0.71 (0.47–1.09) | 0.117 | 0.007 | 0.74 (0.52–1.07) 0.112 | |
| ≤1 | 99 | |||||
| 2 | 53 | |||||
| Etiology | 0.962 | 0.871 | ||||
| HBV/HCV | 118 | |||||
| None | 34 | |||||
| No. of Tumors | 0.002 | 0.76 (0.51–1.13) | 0.171 | 0.767 | ||
| Single | 56 | |||||
| Multiple | 96 | |||||
| Tumor Size | 0.278 | 0.165 | ||||
| ≤5 cm | 24 | |||||
| >5 cm | 128 | |||||
| PVTT | <0.001 | 2.08 (1.32–3.28) | 0.002 | 0.837 | ||
| Without | 57 | |||||
| With | 95 | |||||
| AFP Level | 0.235 | 0.856 | ||||
| ≤400 ng/mL | 81 | |||||
| >400 ng/mL | 71 | |||||
| Child–Pugh Class | 0.007 | 0.88 (0.57–1.37) | 0.582 | 0.689 | ||
| A | 101 | |||||
| B | 51 | |||||
| Duration of Sorafenib | <0.001 | 2.31 (1.45–3.67) | <0.001 | <0.001 | 1.14 (0.78–1.67) 0.488 | |
| <12 months | 100 | |||||
| ≥12 months | 52 | |||||
| TACE Sessions | 0.071 | 0.99 (0.68–1.46) | 0.979 | 0.016 | 1.08 (0.76–1.53) 0.687 | |
| ≤3 | 77 | |||||
| >3 | 75 | |||||
| MWA Treatment | <0.001 | 2.03 (1.18–3.50) | 0.011 | <0.001 | 3.64 (2.37–5.60) <0.001 | |
| Without | 75 | |||||
| With | 77 | |||||
Note: Data in parentheses are 95% confidence intervals.
Abbreviations: HR, hazard ratio; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; HBV, hepatitis B virus; HCV, hepatitis C virus; cm, centimeter; PVTT, portal vein tumor thrombosis; AFP, a-fetoprotein; TACE, transarterial chemoembolization; MWA, microwave ablation.